Hadassah

New Lymphoma Drug, Thanks to Hadassah and Pennsylvania Physician/Scientists

Tuesday, Dec 29 2015

Nephrologist Prof. Michal Dranitzki Elhalel and Pennsylvania Pathologist Prof. Mark L. Tykocinski.

KAHR-102, a new immunotherapy drug to treat lymphoma, based on technology developed by Hadassah Medical Center Nephrologist Prof. Michal Dranitzki Elhalel and Pennsylvania Pathologist Prof. Mark L. Tykocinski, will begin clinical trials in mid-2016 at Hadassah, Tel-Hashomer, and Ichilov (Tel Aviv) medical centers.

Prof. Dranitzki Elhalel, now head of Nephrology at Hadassah, explored possible applications for the fusion protein CTLA4-Fast while a research fellow in 2000 at the University of Pennsylvania laboratory of Prof. Mark L. Tykocinski, who invented CTLA4, now known as KAHR-102. Prof. Tykocinski, then head of the Department of Pathology and Laboratory Medicine at the University of Pennsylvania, is now Dean of the Jefferson Medical School, Philadelphia, PA and Provost and Executive Vice President for Academic Affairs of the Thomas Jefferson University.

When she returned to Hadassah, Prof. Dranitzki Elhalel, with Prof. Tykocinski's encouragement,  continued to study this potential drug in her own laboratory, as well as other fusion proteins of the same class. KAHR-102, she explains,”is a fusion of portions of two naturally occurring human proteins into one chimeric protein with two functional ends. These two functional ends can bring synergistic effects, leading to highly targeted death of specific cells that can bind both sides of the protein, like malignant lymphoma cells.” She adds: “Interestingly, we found out that the resulting fusion protein has a unique structure that strongly increases its potency while conserving its specificity to the malignant lymphoma cells.”

KAHR medical Ltd., based on Prof. Tykocinski's patents, was established in 2007 by Hadasit, Hadassah’s technology transfer company. Prof. Tykocinski is Chair of the Scientific Clinical Advisory Board and Prof. Dranitzki Elhalel serves as KAHR’a Chief Scientist. Prof. Arnold Freedman, head of the Lymphoma Program at Dana Farber Cancer Institute, Boston, has recently joined KAHR’s Scientific Advisory Board.

The KAHR-102 study protocol was recently approved by the Israeli regulatory authorities, clearing the way for the clinical trial to begin mid-2016. The drug company, specializing in cancer and autoimmune disease drugs, reports that its products “form a new generation of biological drugs with great diversity and superior efficacy for the treatment of multiple cancer and autoimmune diseases.”

Comments

From: janine on February 14, 2016
can you have me? I have lymphoma,
From: janine on February 14, 2016
As a person living with lymphoma, I an excited to learn more. Can you help me?
From: Muriel on February 5, 2016
As a person living with lymphoma, I am very anxious to learn the results of the clinical trial. It sounds promising and I really hope it is effective.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Thursday, Sep 14 2017

Hadassah's Head of Emergency Medicine Springs to Action at Bar Mitzvah

Dr. Jacob (Koby) Assaf, head of Emergency Medicine at Hadassah Hospital Ein Kerem, was at a family Bar Mitzvah in a Jerusalem hotel when suddenly a 60-year-old man collapsed right next to him.

READ MORE ›
alt_text

Thursday, Sep 14 2017

Professor, Grandfather, and Cancer Survivor: A Hadassah Story

Following a consultation with Hadassah Endocrinologist and NET specialist Dr. Simona Glasberg, Prof. Bruins underwent numerous tests to determine the source and extent of penetration of this slow-developing type of cancer.

READ MORE ›
alt_text

Thursday, Sep 7 2017

Upgraded Sperm Bank Inaugurated at Hadassah-Mt. Scopus

A spacious, upgraded sperm bank and new laboratories have been inaugurated at Hadassah Hospital Mount Scopus.

READ MORE ›
alt_text

Thursday, Sep 7 2017

Study by Renowned Hadassah Neuropsychiatrist Featured in The Lancet

The work of Dr. Shahar Arzy, head of the Hadassah Medical Organization’s Neuropsychiatry Clinic and the Hadassah-Hebrew University Computational Neuropsychiatry Laboratory, is featured in the September 4, 2017 issue of The Lancet Psychiatry.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More